WO2021160049A1 - 抑菌组合物及其制备方法和用途 - Google Patents
抑菌组合物及其制备方法和用途 Download PDFInfo
- Publication number
- WO2021160049A1 WO2021160049A1 PCT/CN2021/075655 CN2021075655W WO2021160049A1 WO 2021160049 A1 WO2021160049 A1 WO 2021160049A1 CN 2021075655 W CN2021075655 W CN 2021075655W WO 2021160049 A1 WO2021160049 A1 WO 2021160049A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- group
- vaginal
- bacteriostatic composition
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a bacteriostatic composition, a method for inhibiting harmful microorganisms, and a method for regulating vaginal flora. It also relates to a bacteriostatic composition for the preparation of fatty acids and/or their salts for regulating vaginal flora.
- the application in the invention and the preparation method of a bacteriostatic composition are particularly advantageous for preventing a bacteriostatic composition.
- the skin and mucous membranes of the human body are connected to the outside world and are prone to be contaminated with various germs, and can further develop into the colonization, infection, or carry and spread of germs on the skin and/or mucous membranes.
- Using antibacterial products to clean the skin and/or mucous membranes can effectively reduce the pathogen load on the skin and/or mucous membranes, and even kill the bacteria, thereby helping to prevent the infection and spread of the bacteria.
- the bacteria in the female vagina are mainly Lactobacillus, which metabolize the glycogen in the vaginal mucosal epithelial cells to produce acid, keep the vaginal pH in the range of 3.5-4.5, and produce hydrogen peroxide, bacteriocins and other substances , It has inhibitory effect on pathogenic bacteria and conditional pathogenic bacteria, so it is a beneficial bacteria in the vagina, or called "normal vaginal flora".
- Gardnerella vaginalis Prevotella, kinesococcus, Escherichia coli, Staphylococcus, Candida, etc. are also inhabited in the vagina. When the number is small, it is not pathogenic, and when the number is large, it can produce harmful Metabolites, toxins and other substances cause pathological changes and diseases in the human body, so they are called "conditional pathogens".
- Staphylococcus aureus is highly pathogenic and representative; among Candida bacteria, Candida albicans is the most, accounting for more than 70% of the total number of vaginal and/or vulvar Candida infections. Representative.
- vaginal flora When the vaginal flora is abnormal and the number of lactobacilli is low, not only the number of pathogenic bacteria such as Gardnerella vaginalis increases, but the resistance to pathogenic bacteria with strong virulence and pathogenicity is also reduced, resulting in infectious diseases of the reproductive tract.
- the risk of infection is increased, such as the risk of infectious diseases caused by gonococcus, trichomoniasis, chlamydia, mycoplasma, HIV, HPV, etc.
- vaginal microbial diseases are still mainly antibacterial.
- antibacterial treatment can inhibit or kill pathogenic bacteria, it often has an inhibitory or even killing effect on beneficial lactobacilli, resulting in a decrease in vaginal anti-infective power, causing repeated vaginal infections or prolonged infections.
- How to protect the beneficial bacteria in the vagina during antibacterial treatment so as to improve the effectiveness of the prevention and treatment of vaginal infections is still a hot issue in medical research.
- a safe and effective antibacterial product is not only suitable for the cleansing and antibacterial of human skin and mucous membranes, but also for the antiseptic of personal toiletries such as bath products, skin care products and cosmetics, as well as products suitable for medical purposes.
- Antiseptic, medicine, etc. can also be used to inhibit abnormal vaginal flora, restore and/or maintain vaginal lactobacilli, restore and/or maintain normal vaginal flora, restore and/or maintain normal vaginal microecology, so it has a strong The practicality and great market demand.
- An object of the present invention is to provide a bacteriostatic composition.
- Another object of the present invention is to provide a method for inhibiting harmful microorganisms.
- Another object of the present invention is to provide a method for regulating vaginal flora, including inhibiting abnormal vaginal flora, restoring and/or maintaining vaginal lactobacilli.
- Another object of the present invention is to provide the use of fatty acid and/or its salt in preparing a bacteriostatic composition for regulating vaginal flora.
- Another object of the present invention is to provide a method for preparing a bacteriostatic composition.
- the present invention provides a bacteriostatic composition, which comprises the following components:
- fatty acids and/or their salts selected from acetic acid, glycolic acid, lactic acid, propionic acid, levulinic acid, butyric acid, isobutyric acid, hydroxybutyric acid, valeric acid, caproic acid , Heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid, preferably consisting of propionic acid, butyric acid, caproic acid, caprylic acid, capric acid, and undecanoic acid Group, the total content of component (1) in terms of fatty acids is in the range of 0.001-3.00% (w/w);
- the dibasic acid is selected from the group consisting of glutaric acid, adipic acid, and pimelic acid, preferably, the dibasic acid is adipic acid Diacid, the total content of component (2) calculated as dibasic acid is in the range of 0.05-5.00% (w/w);
- aromatic alcohols are selected from the group consisting of benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenethyl alcohol, phenoxyethanol, and cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol
- the total content of component (3) is in the range of 0.03-1.00% (w/w);
- aromatic acids and/or their salts the aromatic acids selected from benzoic acid, p-hydroxybenzoic acid, p-methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and coffee
- the group consisting of acids preferably the group consisting of benzoic acid, cinnamic acid, and p-hydroxybenzoic acid, the total content of component (4) calculated as aromatic acid is in the range of 0.03-1.00% (w/w);
- the bacteriostatic composition adopts one of the following dosage forms: aqueous solutions, water-soluble gels, foams, sprays, ointments, powders, films, capsules, suppositories, and tablets, preferably aqueous solutions , Water-soluble gels, foams, sprays, and ointments.
- the total content of one or more fatty acids and/or their salts is preferably in the range of 0.001-2.00% (w/w), more preferably in the range of 0.001-1.50% (w/w), based on fatty acids Within the range, most preferably in the range of 0.002%-1.25% (w/w); and/or the total content of one or more dibasic acids and/or salts thereof is preferably in the range of 0.10-3.50% (w/w) based on the dibasic acid /w), more preferably in the range of 0.50-2.50% (w/w), most preferably in the range of 0.50-1.50% (w/w); and/or the total content of one or more aromatic alcohols is preferably In the range of 0.03-0.70% (w/w), more preferably in the range of 0.05-0.60% (w/w), most preferably in the range of 0.08-0.50% (w/w); and/or one or more The total content of the aromatic acids and/or their salts is preferably in the range of
- the bacteriostatic composition further contains one or more selected from the group consisting of malic acid, citric acid, succinic acid, tartaric acid, and maleic acid with a total content in the range of 0.10-2.50% (w/w) , Isocitric acid, suberic acid, azelaic acid, and dibasic acid and/or polybasic acid of the group consisting of sebacic acid, and/or its salt, preferably, contains one or more selected from malic acid, Citric acid, dibasic acid and/or polybasic acid of succinic acid, and/or salt thereof.
- the acid and/or its salt has a buffering effect, which can enhance the pH stability of the bacteriostatic composition of the present disclosure, and further enhance the pH adjustment effect of the bacteriostatic composition of the present disclosure on human skin and/or mucosa. .
- the bacteriostatic composition optionally contains one or more monosaccharides and/or oligosaccharides and/ Or polysaccharides: glucose, fructose, mannose, galactose, maltose, isomaltose, sucrose, isomaltulose, lactose, lactulose, trehalose, cellobiose, melibiose, gentiobiose, sucrose , Saccharose, saccharose, saccharose, isomaltotriose, isomalt tetraose, isomalt pentaose, gentio-oligosaccharide, raffinose, panose, malto-oligosaccharide, isomaltulose, Fructooligosaccharide, glucomannan, galacto-oligosaccharide, dextrin, starch, and glycogen; preferably isomaltulose, lactose,
- the sugar-containing bacteriostatic composition of the present disclosure can both inhibit Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, kinesococcus spp.
- Aspergillus, abnormal flora of the skin and/or mucosa, etc. can promote and/or maintain the lactic acid bacteria in the skin and/or mucosa, promote and/or maintain the acidity of the skin and/or mucosa, which can be used for prevention and/or Or to treat the reduction of lactic acid bacteria in the skin and/or mucous membranes, and the imbalance of the flora of the skin and/or mucous membranes, such as the prevention and/or treatment of bacterial vaginosis, or aerobic vaginitis, or atrophic vaginitis, Or used for auxiliary treatment of vaginitis, or recovery after vaginitis treatment, or for the treatment of genital tract infections.
- the bacteriostatic composition optionally contains one or more amino acids and/or salts thereof selected from the following group with a total content in the range of 0.10-6.00% (w/w): L- Glutamic acid, glutamine, L-aspartic acid, asparagine, leucine, isoleucine, phenylalanine, valine, proline, and threonine, preferably total content Glutamic acid and/or its salt, and/or aspartic acid and/or its salt, or a mixture thereof in the range of 0.50-3.00% (w/w).
- amino acids and/or salts thereof selected from the following group with a total content in the range of 0.10-6.00% (w/w): L- Glutamic acid, glutamine, L-aspartic acid, asparagine, leucine, isoleucine, phenylalanine, valine, proline, and threonine, preferably total content Glutamic acid and/or its salt, and/or aspartic acid and
- the bacteriostatic composition containing amino acids and/or their salts of the present disclosure can reduce acid production by lactic acid bacteria, thereby reducing the acidity of skin and/or mucosal parts, and is suitable for regulating the microenvironment of skin and/or mucosal parts, such as for treatment or Adjuvant treatment of cytolytic vaginosis, vaginal vulvar candida disease, etc.
- the bacteriostatic composition optionally contains one or more monoterpenoids or sesquiterpenoids in a total content in the range of 0.001-0.50% (w/w), including but not limited to: Citronellol, linalool, geraniol, nerol, eucalyptol, terpineol, carvol, menthol, and lavender alcohol. Containing monoterpenoids or sesquiterpenoids can not only enhance the bacteriostatic effect of the bacteriostatic composition, but also provide aromatic odor to the composition.
- the bacteriostatic composition optionally contains one or more plant aromatic oils in a total content within the range of 0.0001-0.05% (w/w), including but not limited to: rose essential oil, clove Oil, thyme oil, lavender oil, peppermint oil, mugwort oil, eucalyptus oil, sassafras oil, Litsea cubeba oil, cinnamon oil, bay leaf oil, and thyme oil.
- the plant aroma oil can not only enhance the antibacterial effect of the composition, but also provide the composition with aromatic odor.
- the bacteriostatic composition optionally contains a total content in the range of 0.001-0.50% (w/w) of one or more vitamin substances selected from the following group: vitamin A, vitamin C, Vitamin D and vitamin E.
- the vitamin substances can be either high-purity vitamin substances or plant extracts containing the vitamin substances, which have antioxidant properties or promote skin Cell growth, or regulation of immune function, or maintenance of mucosal epithelial cell integrity, etc., can enhance the stability of the antibacterial composition, or have a protective effect on human skin and/or mucosa.
- the bacteriostatic composition optionally contains one or more components selected from the group consisting of dehydroacetic acid, sodium dehydroacetate, sorbic acid, potassium sorbate, sodium sorbate, sodium Tamycin, bergenin, tropolone, cinnamic aldehyde, kenya acetic acid, chlorogenic acid, 1,2-pentanediol, 1,2-hexanediol, 1,6-hexanediol, 1,2-octanediol, 1,2-decanediol, p-hydroxyacetophenone, 2,4-dihydroxyacetophenone, methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, p-hydroxybenzoic acid Propyl ester, lysozyme, glyceryl monocaprylate, glyceryl monocaprate, and glyceryl monolaurate.
- dehydroacetic acid sodium dehydroacetate
- the components are used to further enhance the bacteriostatic composition of the present disclosure against Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, and Mosquito Bacillus, Aspergillus niger, abnormal flora of skin and/or mucosa, etc., and other harmful microorganisms including but not limited to the antibacterial or antibacterial effect of viruses such as HIV and HPV.
- the antibacterial composition further contains one or more antibacterial drugs, including but not limited to: nitroimidazole drugs such as metronidazole, tinidazole, ornidazole, aminoglycoside drugs Such as gentamicin, tobramycin, amikacin, sisomicin, netilmicin, quinolone drugs such as ciprofloxacin, ofloxacin, levofloxacin, furan drugs such as nifuratel , Nifuroxime, nitrofuran, furazolidone, nitrofurantoin, sulfa drugs such as silver sulfadiazine, sodium sulfacetamide, pyrrole drugs such as clotrimazole, fluconazole, miconazole, ketoconazole, allylamine drugs such as Naftifine, terbinafine, polyene antibiotics such as amphotericin B, nystatin, zymostat, natamycin.
- the antibacterial composition containing antibacterial drugs of the present disclosure is suitable for skin and/or mucous membranes, such as the prevention and/or treatment of bacterial and/or fungal infections of the skin, the prevention and/or treatment of bacterial or fungal infections of the oral mucosa, and the prevention and / Or treatment of bacterial vaginosis of the vaginal mucosa, or aerobic vaginitis, or vaginal vulvar candida, etc.
- the bacteriostatic composition adopts one of the following dosage forms: an aqueous solution, a water-soluble gel, a foam, a spray, and an ointment; the aqueous solution, or a water-soluble gel
- the pH value of the preparation, foam, spray, or ointment is in the range of 3.1-4.8, preferably the pH value is in the range of 3.6-4.6, and more preferably the pH value is in the range of 3.8-4.4.
- the bacteriostatic composition is a water-soluble gel
- the water-soluble gel also contains one or more non-flowing, viscous, water-soluble colloidal matrix, including but not limited to xanthogen Gum, carbomer, polycarbophil, dextran, glucomannan, tragacanth, tragacanth, methyl cellulose (MC), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC) ), hydroxyethyl methyl cellulose (HEMC), hydroxypropyl methyl cellulose (HPMC), preferably xanthan gum and carbomer.
- xanthogen Gum carbomer
- polycarbophil dextran
- glucomannan glucomannan
- tragacanth tragacanth
- methyl cellulose methyl cellulose
- CMC carboxymethyl cellulose
- HEC hydroxyethyl cellulose
- HEMC hydroxyethyl methyl cellulose
- HPMC hydroxypropyl
- the bacteriostatic composition of the present disclosure has an inhibitory effect on harmful microorganisms, wherein the harmful microorganisms include but are not limited to Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, kinesobacterium, Aspergillus niger, abnormal flora of skin and/or mucous membrane, other various pathogenic or conditionally pathogenic aerobes, facultative aerobes, anaerobes, molds , And viruses such as HPV and HIV.
- Candida Candida
- Staphylococcus aureus Escherichia coli
- Pseudomonas aeruginosa Gardnerella vaginalis
- Prevotella kinesobacterium
- Aspergillus niger abnormal flora of skin and/or mucous membrane
- other various pathogenic or conditionally pathogenic aerobes facultative aerobes,
- the bacteriostatic composition of the present disclosure can be used for cleaning and/or bacteriostasis and/or disinfection of human skin and/or mucosa, such as cleaning and/or bacteriostasis and/or disinfection of vaginal mucosa, and can also be used for Anti-corrosion of various bath products, shampoo products, skin care products, cosmetics and other personal toiletries, or anti-corrosion of products and medicines used for medical purposes.
- the bacteriostatic composition of the present disclosure can be used as a therapeutic product, or an effective component thereof, or a preservative thereof.
- the therapeutic product includes, but is not limited to, medicines, disinfectants, mucosal surface microbicides, Antibacterial agents, bacteriostatic agents, micro-ecological regulators, flora regulators, micro-environment regulators, microbial regulators, disposable medical supplies, etc., or medical devices, pharmaceutical devices, disinfection devices, and vaginal devices
- the components of the form exist.
- the bacteriostatic composition of the present disclosure is a non-therapeutic product, or an effective component thereof, or a preservative thereof, wherein the non-therapeutic product exists in one of the following groups: health care products, Hygiene products, personal toiletries, cosmetics, disposable sanitary products, cleaning products, daily necessities, micro-ecological care products, deodorants, lubricants, humectants, lotions, detergents, curing agents, antipruritic agents, refreshing Or as a component of sanitary napkins, sanitary pads, and tampons.
- the bacteriostatic composition of the present invention is a bacteriostatic composition for vagina
- the bacteriostatic composition for vagina includes the following components:
- the total content of propionic acid, butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, or their mixtures in the inner surface is more preferably in the range of 0.002-1.25% (w/w);
- dibasic acids and/or their salts selected from the following group with a total content of 0.50-2.50% (w/w) in terms of dibasic acid: glutaric acid, adipic acid , Pimelic acid, preferably adipic acid with a total content of 0.50-1.50% (w/w);
- One or more aromatic acids and/or their salts selected from the group consisting of benzoic acid, p-hydroxybenzoic acid, para Methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and caffeic acid, preferably benzoic acid, cinnamic acid, p-hydroxybenzoic acid, or their total content in the range of 0.08-0.20% (w/w) mixture.
- the bacteriostatic composition for vagina adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet, preferably Aqueous solutions, water-soluble gels, foams, sprays, and ointments.
- the bacteriostatic composition for vagina of the present disclosure further contains one or more estrogenic substances selected from the group consisting of diethylstilbestrol, diethylstilbestrol, Hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol cyclopentyl ether, ethinyl estradiol, and proestrene, preferably estriol, proestrene .
- one or more estrogenic substances selected from the group consisting of diethylstilbestrol, diethylstilbestrol, Hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol cyclopentyl ether, ethinyl estradiol, and proestrene, preferably estriol, proestrene .
- vaginal bacteriostatic composition containing estrogen substances of the present disclosure can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli, and is especially suitable for menopause or postmenopause or postpartum.
- the bacteriostatic composition for vagina of the present disclosure further contains one or more phytoestrogens selected from the group consisting of soybeans with a total content in the range of 0.001-1.00% (w/w) Glycosides, daidzein, glycitein, puerarin, estradiol, genistein, equol, apigenin, genistein, genistein, chickpein, couestrol, awn Pseudoflavin, resveratrol, flax lignans, and lignans.
- phytoestrogens selected from the group consisting of soybeans with a total content in the range of 0.001-1.00% (w/w) Glycosides, daidzein, glycitein, puerarin, estradiol, genistein, equol, apigenin, genistein, genistein, chickpein, couestrol, awn Pse
- the phytoestrogens-containing vaginal bacteriostatic composition of the present disclosure can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli, and is especially suitable for menopause or postmenopausal or postpartum.
- the bacteriostatic composition for vagina of the present disclosure can selectively contain water, xanthan gum, or carbomer and other different dosage bases according to different applicable requirements, or optionally further contain one or more of the aforementioned groups.
- Dibasic acids such as malic acid, citric acid, succinic acid and/or their salts, polybasic acids and/or their salts, and/or dehydroacetic acid with a total content within the range of 0.10-2.50% (w/w)
- Amino acid substances such as glutamic acid and/or its salt, aspartic acid and/or its salt within the range, and/or citronellol with a total content of 0.001-0.50% (w/w),
- the bacteriostatic composition for vagina of the present disclosure has an inhibitory effect on the abnormal flora in the vagina, but has a recovery and/or maintenance and/or promotion effect on the lactobacilli in the vagina, and can be used to restore and/or maintain the normal bacteria in the vagina Group, restore and/or maintain the normal microecology of the vagina, restore and/or maintain the normal acidity of the vagina.
- the bacteriostatic composition for vagina of the present disclosure can be used to clean and care the vagina and/or vulva, and/or reduce and/or eliminate vaginal vulva itching, and/or pain, and/or dryness, and/or irritation, and/or Or sexual intercourse discomfort, and/or alleviate and/or eliminate abnormal vaginal discharge, and/or leucorrhea peculiar smell, etc., and for the prevention and/or treatment and/or adjuvant treatment of vaginal flora imbalance, and/or bacterial vaginosis, and/or Or aerobic vaginitis, and/or cytolytic vaginosis, and/or vaginal vulvovaginal candida, and/or atrophic vaginitis, etc.
- the present invention also provides a method for inhibiting harmful microorganisms, including the step of using a bacteriostatic composition, wherein the bacteriostatic composition contains:
- fatty acids and/or their salts selected from acetic acid, glycolic acid, lactic acid, propionic acid, levulinic acid, butyric acid, isobutyric acid, hydroxybutyric acid, valeric acid, caproic acid , Heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid, preferably free of propionic acid, butyric acid, caproic acid, caprylic acid, capric acid, and undecanoic acid Group; the total content of component (1) in terms of fatty acids is in the range of 0.001-3.00% (w/w), preferably in the range of 0.001-2.00% (w/w), more preferably in the range of 0.001-1.50% (w/ w) in the range, most preferably in the range of 0.002%-1.25% (w/w);
- dibasic acids and/or salts thereof is selected from the group consisting of glutaric acid, adipic acid, and pimelic acid, preferably adipic acid;
- the total content of component (2) is in the range of 0.05-5.00% (w/w), preferably in the range of 0.10-3.50% (w/w), more preferably in the range of 0.50-2.50% (w/w) , Most preferably in the range of 0.50-1.50% (w/w);
- aromatic alcohol is selected from the group consisting of benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenethyl alcohol, phenoxyethanol, and cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol , Or their mixture; the total content of component (3) is in the range of 0.03-1.00% (w/w), preferably in the range of 0.03-0.70% (w/w), more preferably in the range of 0.05-0.60% (w /w), most preferably in the range of 0.08-0.50% (w/w);
- aromatic acids and/or their salts the aromatic acids selected from benzoic acid, p-hydroxybenzoic acid, p-methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and coffee
- the group consisting of acid is preferably a group consisting of benzoic acid, cinnamic acid, and p-hydroxybenzoic acid; the total content of component (4) calculated as aromatic acid is in the range of 0.03-1.00% (w/w), preferably In the range of 0.03-0.50% (w/w), more preferably in the range of 0.05-0.25% (w/w), most preferably in the range of 0.08-0.20% (w/w).
- the bacteriostatic composition adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet, preferably an aqueous solution Agents, water-soluble gels, foams, sprays, and ointments.
- the harmful microorganisms described in the method for inhibiting harmful microorganisms of the present disclosure include but are not limited to at least one of the following groups of microorganisms: Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa Spores, Gardnerella vaginalis, Prevotella, Animus, Aspergillus niger, abnormal flora of skin and/or mucous membranes, other various pathogenic or conditionally pathogenic aerobic bacteria, facultative Aerobic bacteria, anaerobes, molds, and viruses HPV, HIV, etc.
- Candida Staphylococcus aureus
- Escherichia coli Escherichia coli
- Pseudomonas aeruginosa Spores Gardnerella vaginalis
- Prevotella Animus
- Aspergillus niger abnormal flora of skin and/or mucous membranes
- the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure can be used for cleaning and/or bacteriostasis and/or disinfection of human skin and/or mucous membranes, such as cleaning and/or inhibiting vaginal mucosa.
- Bacteria and/or disinfection can also be used for the antiseptic of various bath products, or shampoo products, or skin care products, or cosmetics and other personal toiletries, or used for the antiseptic of products and medicines for medical purposes.
- the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure is a therapeutic product, or an effective component thereof, or a preservative thereof.
- the therapeutic product includes, but is not limited to, medicine, disinfection Agents, antibacterial agents, bacteriostatic agents, mucosal surface microbicides, flora regulators, microecological regulators, microenvironment regulators, microbial regulators, disposable medical supplies, etc., or medical devices, or pharmaceutical devices, Or disinfection equipment, and a component of vaginal equipment.
- the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure is a non-therapeutic product, or an effective component thereof, or a preservative thereof, and the non-therapeutic product includes but is not limited to health care Supplies, personal toiletries, cosmetics, hygiene products, disposable hygiene products, cleaning products, daily necessities, micro-ecological care products, deodorants, lubricants, humectants, lotions, detergents, curing agents, antipruritic agents , Fresheners, etc., or can be used as a component of sanitary products or cleaning care products, such as sanitary napkins, or sanitary pads, or tampons.
- the bacteriostatic composition described in the method for inhibiting harmful microorganisms of the present disclosure is used for preservation, it is necessary to make bath products, or shampoo products, or skin care products, or cosmetics, or medicines, and other products for medical purposes, etc.
- the content of each component of the bacteriostatic composition described in the present disclosure contained in the product that is, the total content of one or more fatty acids and/or their salts based on fatty acids, and one based on dibasic acid
- the present invention also provides a method for regulating vaginal flora, wherein regulating vaginal flora includes at least one of the following: inhibiting abnormal vaginal flora, restoring and/or maintaining vaginal lactobacilli, and the method includes using vaginal
- the step of the bacteriostatic composition wherein the vaginal bacteriostatic composition contains one or more fatty acids and/or salts thereof with a total content of 0.001-2.00% (w/w) calculated as fatty acids, and
- the fatty acid is selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid, and preferably the total content is 0.001-1.50% (w/ w) within the range, more preferably within the range of 0.002-1.25% (w/w) selected from the group consisting of butyric acid, ca
- the bacteriostatic composition for vagina adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet; Preferred are aqueous solutions, water-soluble gels, foams, sprays, and ointments.
- the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present invention further contains a dibasic acid with a total content in the range of 0.50-2.50% (w/w) Or multiple dibasic acids and/or salts thereof, the dibasic acid is selected from the group consisting of glutaric acid, adipic acid, and pimelic acid, preferably the total content is in the range of 0.50-1.50% (w/w) Adipic acid, and/or its salt.
- the combination of the dibasic acid such as adipic acid and/or its salt and the fatty acid such as butyric acid and/or its salt of the present disclosure can enhance the antibacterial effect of the fatty acid and/or its salt against Candida albicans.
- the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present invention further contains one or more selected from the group consisting of a total content in the range of 0.05-0.60% (w/w) Group of aromatic alcohols: benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenoxyethanol, phenoxyethanol, cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol, or cinnamyl alcohol with a total content in the range of 0.08-0.50% (w/w) Their mixture.
- the combination of the aromatic alcohols such as phenethyl alcohol and the fatty acids such as butyric acid and/or their salts of the present disclosure can enhance the resistance of the fatty acids and/or their salts to Candida albicans, Staphylococcus aureus, Escherichia coli, and Antibacterial effect of abnormal vaginal flora.
- the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present invention further contains one or one whose total content in terms of aromatic acid is within the range of 0.05-0.25% (w/w)
- aromatic acid is selected from the group consisting of benzoic acid, p-hydroxybenzoic acid, p-methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and caffeic acid, preferably Benzoic acid, cinnamic acid, p-hydroxybenzoic acid, or their mixtures with a total content in the range of 0.08-0.20% (w/w).
- the combination of the aromatic acid such as benzoic acid and/or its salt and the fatty acid such as butyric acid and/or its salt of the present disclosure can enhance the effect of the fatty acid and/or its salt on Candida albicans, Staphylococcus aureus, and large intestine. Antibacterial effect of Escherichia and abnormal vaginal flora.
- the vaginal bacteriostatic composition described in the method for regulating vaginal flora of the present invention contains: (1) a total content of fatty acids in the range of 0.001-2.00% (w/w) One or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid Group, preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid , Or their mixture of fatty acids, and/or their salts; (2) One or more dibasic acids with a total content of 0.50-2.50% (w/w) in terms of dibasic acids and / Or
- dibasic acid such as adipic acid and/or its salt
- aromatic alcohol such as phenethyl alcohol
- fatty acid such as butyric acid and/or its salt of the present disclosure
- the vaginal bacteriostatic composition described in the method for regulating vaginal flora of the present disclosure contains: (1) a total content of fatty acids in the range of 0.001-2.00% (w/w) One or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid Group, preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, Or their mixtures of fatty acids and/or their salts; (2) one or more dibasic acids and/or their total content in the range of 0.50-2.50% (w/w) calculated as dibasic acids Salt,
- dibasic acid such as adipic acid and/or its salt
- aromatic acid such as benzoic acid and/or its salt
- fatty acid such as butyric acid and/or its salt of the present disclosure
- the vaginal bacteriostatic composition described in the method for regulating vaginal flora of the present disclosure contains: (1) a total content of fatty acids in the range of 0.001-2.00% (w/w) One or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid Group, preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, Or their mixture of fatty acids and/or their salts; (2) One or more aromatic alcohols selected from the following group with a total content in the range of 0.05-0.60% (w/w): benzyl alcohol
- aromatic alcohols such as phenethyl alcohol, aromatic acids such as benzoic acid and/or their salts, and fatty acids such as butyric acid and/or their salts of the present disclosure has synergy with Candida albicans, Staphylococcus aureus, Escherichia coli, etc. Antibacterial effect, and has an inhibitory effect on abnormal vaginal flora.
- the vaginal bacteriostatic composition in the method for regulating vaginal flora of the present disclosure contains: (1) one with a total content of fatty acids in the range of 0.001-2.00% (w/w) Or more fatty acids and/or their salts, the fatty acids selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, undecylenic acid, and lauric acid , Preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, undecanoic acid, or Fatty acids and/or their salts in the group consisting of their mixtures; (2) One or more dibasic acids and/or dibasic acids with a total content of 0.50-2.50% (w/w/w)
- the combination of dibasic acid such as adipic acid and/or its salt, aromatic alcohol such as phenethyl alcohol, aromatic acid such as benzoic acid and/or its salt, and fatty acid such as butyric acid and/or its salt of the present disclosure is effective against Candida albicans , Staphylococcus aureus, Escherichia coli, etc. have a synergistic antibacterial effect, as well as an inhibitory effect on abnormal vaginal flora. After the bacteriostatic composition is applied to the vagina, the abnormal flora in the vagina is significantly reduced, and the lactobacilli are significantly increased.
- the composition has the advantages of inhibiting the abnormal vaginal flora, restoring and/or maintaining and/or promoting the lactobacilli in the vagina And the role of restoring and/or maintaining the normal acidity of the vagina.
- the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present disclosure further contains a total content of one or more selected from within the range of 0.001-1.00% (w/w)
- the following group of estrogen substances diethylstilbestrol, hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol cyclopentyl ether, ethinyl estradiol, proestrone Of these, estriol and proestrene are preferred.
- Estrogenic substances can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli.
- the antibacterial composition containing estrogen substances of the present disclosure is especially suitable for menopause or postmenopausal or postpartum.
- the bacteriostatic composition for vagina described in the method for regulating vaginal flora of the present disclosure further contains one or more selected from the group consisting of a total content in the range of 0.001-1.00% (w/w) Phytoestrogens in the following group: daidzein, daidzein, glycitein, puerarin, pseudoestrone, genistein, equol, apigenin, genistein, genistein, chicken Glycinin, couestrol, formononetin, resveratrol, flax lignans, and lignans.
- Phytoestrogens can promote the synthesis of glycogen in vaginal mucosal epithelial cells and promote the growth of beneficial lactobacilli.
- the antibacterial composition containing phytoestrogens of the present disclosure is especially suitable for menopause or postmenopausal or postpartum.
- the method for regulating vaginal flora of the present invention includes applying a vaginal bacteriostatic composition to restore and/or maintain the normal vaginal flora and/or restore and/or maintain the normal vaginal microecology , And/or restore and/or maintain the normal acidity of the vagina, and/or clean and care for the vagina and/or vulva, and/or reduce and/or eliminate vaginal vulvar itching, and/or pain, and/or dryness, and/or Stimulate, and/or discomfort during sexual intercourse, and/or reduce and/or eliminate abnormal leucorrhea and/or leucorrhea peculiar smell.
- the method for regulating vaginal flora of the present invention includes using a vaginal bacteriostatic composition for the prevention and/or treatment of vaginal flora disorders, and/or bacterial vaginosis, and/or aerobic bacteria Vaginitis, and/or cytolytic vaginosis, and/or vaginal vulvovaginal candida, and/or atrophic vaginitis.
- the present invention also provides the use of fatty acids and/or their salts in preparing bacteriostatic compositions for regulating vaginal flora.
- the fatty acids are selected from the group consisting of butyric acid, valeric acid, caproic acid, heptanoic acid, caprylic acid, pelargonic acid, and decanoic acid.
- the total content of the fatty acid and/or its salt in the composition is 0.001-2.00% (w/ w) within the range; preferably the total content is within the range of 0.001-1.50% (w/w), more preferably within the range of 0.002-1.25% (w/w) selected from butyric acid, caproic acid, caprylic acid, capric acid, ten The fatty acid and/or its salt of a monoacid or a mixed group of these.
- the fatty acids and/or their salts used in the TM have the same concentration or properties.
- vaginal flora the use of the fatty acid and/or its salt according to the present invention in the preparation of a bacteriostatic composition for regulating vaginal flora, wherein the regulation of vaginal flora is the same as in the method for regulating vaginal flora of the present disclosure.
- the type of vaginal flora is the same, that is, it includes at least one of the following: inhibiting abnormal vaginal flora, restoring and/or maintaining vaginal lactobacilli.
- the use of the fatty acid and/or its salt according to the present invention in the preparation of a bacteriostatic composition for regulating vaginal flora includes applying a vaginal bacteriostatic composition to Restore and/or maintain the normal vaginal flora, and/or restore and/or maintain the normal vaginal microecology, and/or restore and/or maintain the normal acidity of the vagina, and/or clean and care for the vagina and/or vulva, and/or Or reduce and/or eliminate vaginal genital pruritus, and/or pain, and/or dryness, and/or irritation, and/or discomfort during sexual intercourse, and/or reduce and/or eliminate abnormal vaginal discharge and/or leucorrhea peculiar smell.
- the use of the fatty acid and/or its salt according to the present invention in the preparation of a bacteriostatic composition for regulating vaginal flora includes applying a vaginal bacteriostatic composition to Prevention and/or treatment of vaginal flora imbalance, and/or bacterial vaginosis, and/or aerobic vaginosis, and/or cytolytic vaginosis, and/or vaginal vulvovaginal candida, and/or Or atrophic vaginitis.
- the present invention also provides a method for preparing a bacteriostatic composition.
- the preparation method includes the following steps: adding the following components to an excipient base, wherein the excipient base is an aqueous solution or a water-soluble colloid or foam Excipient base for dosage forms or suppositories or tablets:
- One or more fatty acids and/or their salts with a total content of 0.001-3.00% (w/w) in terms of fatty acids the fatty acids being selected from acetic acid, glycolic acid, lactic acid, propionic acid, acetyl
- One or more dibasic acids and/or their salts selected from the group consisting of glutaric acid and adipic acid with a total content in the range of 0.05-5.00% (w/w) based on dibasic acid , Pimelic acid, preferably adipic acid;
- aromatic alcohols selected from the following group with a total content within the range of 0.03-1.00% (w/w): benzyl alcohol, 2,4-dichlorobenzyl alcohol, phenethyl alcohol, phenoxyethanol, And cinnamyl alcohol, preferably phenethyl alcohol, cinnamyl alcohol, or a mixture thereof.
- aromatic acids and/or their salts selected from the group consisting of benzoic acid, p-hydroxybenzoic acid, p-hydroxybenzoic acid and Methoxybenzoic acid, salicylic acid, cinnamic acid, gentisic acid, and caffeic acid, preferably benzoic acid, cinnamic acid, p-hydroxybenzoic acid, or a mixture thereof;
- composition adopts one of the following dosage forms: aqueous solution, water-soluble gel, foam, spray, ointment, powder, film, capsule, suppository, and tablet, preferably aqueous solution, or Water-soluble gel, or foam, or spray, or ointment.
- the total content of the one or more fatty acids and/or salts thereof added in the preparation method is preferably in the range of 0.001-2.00% (w/w), more preferably Within the range of 0.001-1.50% (w/w), most preferably within the range of 0.002%-1.25% (w/w); and/or the added one or more dibasic acids in terms of dibasic acid And/or the total content of its salt is preferably in the range of 0.10-3.50% (w/w), more preferably in the range of 0.50-2.50% (w/w), most preferably in the range of 0.50-1.50% (w/w) And/or the total content of the added one or more aromatic alcohols is preferably in the range of 0.03-0.70% (w/w), more preferably in the range of 0.05-0.60% (w/w), most preferably In the range of 0.08-0.50% (w/w); and/or the total content of one or more aromatic acids and/or their salts added in terms of aromatic acids is preferably in the range of 0.00
- a non-flowing, viscous, water-soluble colloidal matrix should be selected, which enables the composition to uniformly contact the vaginal mucosa and stays for a long time to exert its effect.
- the matrix is xanthan gum, and/or carbomer, and/or polycarbophil, and/or dextran, and/or glucomannan, and/or tragacanth, and / Or tragacanth gum, and/or methyl cellulose (MC), and/or carboxymethyl cellulose (CMC), and/or hydroxyethyl cellulose (HEC), and/or hydroxyethyl methyl cellulose (HEMC) and/or hydroxypropyl methylcellulose (HPMC), preferably xanthan gum and carbomer.
- the composition can be prepared according to the following process: (1) one or more fatty acids and/or their salts, such as propionic acid and/or their sodium salts, and (2) one or more fatty acids and/or their sodium salts.
- Various dibasic acids and/or their salts such as adipic acid and/or their salts
- one or more aromatic alcohols such as phenethyl alcohol
- one or more aromatic acids and/or their salts such as Benzoic acid and/or its sodium salt
- One or more colloidal bases such as xanthan gum, and other components, etc., mix well, add distilled water quantitatively, stir and mix, dissolve each component and swell the colloidal matrix It is a homogeneous colloid;
- the pH of the composition is adjusted to the range of 3.1-4.8, preferably 3.6-4.6, more preferably 3.8-4.4 with acid and/or alkali.
- further sterilization treatment can be performed, and the sterilization can choose the following processes: radiation sterilization, high temperature sterilization (such as 115.6°C, 15-20 minutes; or 100°C, 30 minutes sterilization), or intermittent Sterilize (such as first 80°C for 30 minutes, then 36°C for 5-10 hours, then 80°C for 30 minutes, then 36°C for 5-10 hours, and finally 80°C for 30 minutes).
- radiation sterilization high temperature sterilization (such as 115.6°C, 15-20 minutes; or 100°C, 30 minutes sterilization), or intermittent Sterilize (such as first 80°C for 30 minutes, then 36°C for 5-10 hours, then 80°C for 30 minutes, then 36°C for 5-10 hours, and finally 80°C for 30 minutes).
- components such as benzoic acid and/or its sodium salt are separately formulated into a solution, filtered and sterilized, and then added to the sterilized water-soluble colloidal matrix.
- the above-mentioned components other than xanthan gum can be mixed, water is added, the components are dissolved, sterilized, and divided; or the components are dissolved, filtered, and divided. .
- the selection of the base and the specific preparation process can refer to methods known to those skilled in the art, for example, in the "Pharmaceutical Science” edited by Fang Liang (see Reference 1 for details) The method of introduction.
- the prepared tablets when preparing tablets, methods known to those skilled in the art can be referred to, such as the method introduced in "Pharmaceuticals” edited by Fang Liang (for details, see Reference 2), the quantitative fatty acids and / Or its salt, dibasic acid and/or its salt, aromatic alcohol, aromatic acid and/or its salt, and other components, etc., mix uniformly with filling auxiliary materials, and press directly to obtain tablets; auxiliary materials may also be added Ingredients, such as lubricants such as magnesium stearate or disintegrating agents such as sodium carboxymethyl starch, are mixed uniformly and compressed.
- the prepared tablets can also be dispensed into a drug delivery device, or a sterilization device, or a medical device, or a drug device.
- the fatty acids and/or their salts, dibasic acids and/ Or its salts, aromatic alcohols, aromatic acids and/or its salts and other components such as sodium benzoate, sodium propionate, caproic acid, phenethyl alcohol, adipic acid, and other components, plus the corresponding auxiliary components to make Powders, films, tablets, or capsules, and then built into sanitary napkins, sanitary pads, or tampons, etc.
- the fatty acids of the present disclosure And/or its salt, dibasic acid and/or its salt, aromatic alcohol, aromatic acid and/or its salt and other components, such as sodium propionate, caproic acid, phenethyl alcohol, sodium benzoate, adipic acid, and other components It is graded and attached to the inner layer materials of sanitary napkins or sanitary pads or tampons with appropriate auxiliary material components.
- each unit dosage form when preparing dosage forms such as capsules, suppositories, or tablets, contains a specific content range of each component of the composition of the present disclosure.
- each unit dosage form contains one or more fatty acids and/or their salts in a total amount of 0.00005-0.15 g in terms of fatty acids, and a total amount of 0.0025-0.25 g in terms of dibasic acid and/or polybasic acid.
- each unit dosage form contains 0.00005-0.100 grams of one or more fatty acids and/or their salts in a total amount of 0.00005-0.100 grams, and the total amount is 0.005 in terms of dibasic acid and/or polybasic acid -0.175 grams of one or more dibasic acids and/or salts thereof, the total amount of one or more aromatic alcohols is 0.0015 to 0.035 grams, and the total amount of aromatic acids is 0.0015 to 0.025 grams of one or Various aromatic acids and/or their salts.
- organic acids or their salts used in the preparation method of the present disclosure such as fatty acids and/or their salts, or dibasic acids and/or their salts, or aromatic acids and/or their salts, are soluble in water and are unionized
- the ratio of molecules to ionized ions, unionized molecules to ionized ions depends on the pH value of the solution and the pKa value of the ionization constant of the organic acid. It can be seen that the organic acid and its salt are both organic acid molecules or organic acid radical ions after being dissolved in water. From this point of view, there is no substantial difference between the two.
- Commonly used preservatives for skin care products, cosmetics, and bath products, as well as common preservatives for medical products and pharmaceuticals, such as chlorobutanol, benzalkonium chloride, etc. usually have an inhibitory effect on Lactobacillus and other lactic acid bacteria.
- the prior art (such as PCT/CN2017/105296, ZL201080036139, US8765819) discloses some low-concentration bacteriostatic agents, such as low-concentration phenethyl alcohol, propionic acid and/or its salt, and/or benzoic acid and/or its salt. These low-concentration bacteriostatic agent-containing compositions can inhibit Escherichia coli and Staphylococcus aureus.
- the inhibition rate of Escherichia coli and Staphylococcus aureus can reach more than 50%, the inhibition rate of Candida albicans is low, and the inhibition rate is less than 50%.
- bacteriostatic agent can enhance the bacteriostatic effect on Candida albicans.
- concentration of bacteriostatic agent can not only enhance the antibacterial effect of the antibacterial combination, but also Effectively inhibit Escherichia coli, Staphylococcus aureus, etc., and the inhibition rate of Candida albicans is greater than 50%.
- concentration of the bacteriostatic agent the stronger the inhibitory effect on Lactobacillus and other lactic acid bacteria.
- bacteriostatic composition that effectively inhibits harmful microorganisms but does not inhibit beneficial bacteria such as Lactobacillus, and can be used for skin and/or mucous membrane cleaning or bacteriostasis or disinfection, and can be used as an antiseptic for skin care products, cosmetics, bath products, etc.
- beneficial bacteria such as Lactobacillus
- the inventor continues to conduct in-depth research on antibacterial compositions as preservatives for medical products and medicines. It was found that suitable fatty acids and/or their salts selectively combined with dibasic acids, aromatic alcohols, aromatic acids, etc., not only have a synergistic antibacterial effect on Staphylococcus aureus and Escherichia coli, but also on Candida albicans, etc.
- the bacteriostatic composition prepared accordingly is used in the vagina, which can significantly reduce the abnormal flora of the vagina and increase the lactobacillus, and has the effect of regulating the vaginal flora and the acidity of the vagina. Therefore, the bacteriostatic composition of the present disclosure can be used for cleaning or bacteriostasis or disinfection of the skin and/or mucous membranes; and for the preservation of bath products, skin care products, and cosmetics, as well as for the preservation of medical products, medicines, and the like.
- Lactobacillus refers to the bacteria of the genus Lactobacillus, English Lactobacillus, is a gram-positive, rod-shaped, non-spore, capable of fermenting metabolizable sugars to produce large amounts of lactic acid bacteria, including hundreds of species and subspecies.
- Lactobacillus is a general term for bacteria that can metabolize fermentable carbohydrates to produce large amounts of lactic acid, including 18 genera and more than 200 species of bacteria. Among them, Lactobacillus is also a kind of lactic acid bacteria.
- Normal vaginal flora refers to the Nugent score of vaginal flora with a score of 1-3.
- the bacteria in the vagina are mainly Lactobacillus and the number is large, and the number of other types of bacteria is small.
- the "other types of bacteria” include gram-positive cocci such as staphylococcus, streptococcus, etc., gram-negative bacilli such as Gardnerella vaginalis, Escherichia coli, etc., and gram-negative cocci such as Veillonella, etc. Sexual anaerobic Prevotella, kinetic Campylobacter, etc.
- Vaginal abnormal flora refers to the Nugent score of 5-10 points for the vaginal flora.
- the number of lactobacilli in the vagina is small, and the number of other types of bacteria is large.
- the "other types of bacteria” include gram-positive cocci such as staphylococcus, streptococcus, etc., gram-negative bacilli such as Gardnerella vaginalis, Escherichia coli, etc., and gram-negative cocci such as Veillonella, etc.
- Hard microorganisms generally refer to various pathogenic microorganisms with strong pathogenicity, or pathogenic microorganisms of various conditions that cause disease when the body's immunity is reduced, or those that cause food, medicine, cosmetics, and sanitary products to spoil.
- Microorganisms including but not limited to the following groups of microorganisms: Candida, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Gardnerella vaginalis, Prevotella, Animus Campylobacter, Aspergillus niger , Skin and/or mucous membrane abnormal flora, and viruses HPV, HIV, etc.
- Components refer to various ingredients in the composition, including bacteriostatic agents and other ingredients that have no bacteriostatic effect.
- Bacteriostatic agent refers to various ingredients or combinations thereof that have bacteriostatic effects, and is not limited to conventional bacteriostatic agents or combinations thereof recognized by those skilled in the art.
- Bacteriostatic rate refers to the test method and judgment standard in Appendix C of GB 15979-2002 "Sanitary Standards for Disposable Sanitary Products”. Antibacterial rate of bacteria.
- Bacteriostatic effect refers to the inhibitory effect of bacteriostatic agents on bacteria, fungi, etc.
- the antibacterial effect is judged by the level of antibacterial rate, and the specifics are as follows: antibacterial rate>50%, it is “has antibacterial effect”; antibacterial rate>90%, it is “strong antibacterial effect”.
- Low-concentration bacteriostatic agent refers to a bacteriostatic agent with a low concentration of ⁇ 50% against Candida albicans.
- High-concentration bacteriostatic agent refers to a bacteriostatic agent with a high concentration of antibacterial rate>50% against Candida albicans.
- “Synergy antibacterial effect” refers to the antibacterial rate of the combination of two or more antibacterial agents against Escherichia coli or Staphylococcus aureus or Candida albicans, which is higher than the antibacterial rate of each antibacterial agent alone. The sum is more than 15% higher.
- compositions of the antibacterial composition are a variety of exemplary compositions of the antibacterial composition.
- exemplary components in the composition refer to the following substances:
- the raw materials were weighed according to the following ratio, and 100 g of the composition was prepared basically according to the method of Example 1.
- Glutamic acid 0.76g, glutamine 0.34g, aspartic acid 0.60g, asparagine 0.98g, isoleucine 0.31g, methionine 0.35g, phenylalanine 0.20g, valine 0.46g, bright 0.78 g of acid and 0.89 g of proline;
- the raw materials were weighed according to the following ratio, and 100 g of the composition was prepared basically according to the method of Example 1.
- a tablet containing 60 mg of adipic acid, 5 mg of sodium benzoate, 30 mg of propionic acid, and 60 mg of sucrose per tablet was prepared.
- vaginal suppository containing 60 mg of adipic acid, 5 mg of sodium benzoate, 30 mg of propionic acid, and 60 mg of maltose per capsule was prepared.
- This example is used to verify the effect of the composition.
- the antibacterial rate of Candida albicans is significantly higher than any three of them.
- the bacteriostatic rate of the solution of the combination of components is also significantly higher than the sum of the bacteriostatic rates of the four components acting separately, suggesting that these four components have a synergistic antibacterial effect on Candida albicans.
- cinnamic acid 0.05-0.10% salicylic acid can inhibit the white false color of the solution containing the three-component combination of "1.50% adipic acid, 0.45% phenethyl alcohol, and 1.50% propionic acid".
- the effect of silk yeast has an effect or a significant effect, and the antibacterial effect increases as the concentration of cinnamic acid or salicylic acid increases.
- the basic antibacterial liquid has antibacterial effect on Candida albicans, and the antibacterial rate is 53.77%;
- the basic antibacterial solution was added with 1.00% citric acid, 0.70% malic acid, and 0.61% succinic acid.
- the antibacterial rates against Candida albicans were 49.25%, 54.77%, and 53.27%, respectively.
- cinnamyl alcohol has a significant effect on the inhibition of Candida albicans by a solution of "1.50% pimelic acid, 0.20% sodium benzoate, and 2.00% propionic acid", and the antibacterial effect is enhanced.
- the pH value of the solution is 3.86
- the 0.04% and 0.06% puerarin contained in the components respectively have no effect on the inhibitory effect of Candida albicans, and the antibacterial effect is not weakened. .
- estrogenic substances such as diethylstilbestrol, hexestrol, estradiol, estrone, estriol, nylestriol, ethinyl estradiol, ethinyl estradiol, ethinyl estradiol, Proestene, and other phytoestrogens, such as daidzein, daidzein, glycitein, puerarin, estradiol, genistein, equol, apigenin, genistein, dyes Lignin, chickpexanthin, couestrol, formononetin, resveratrol, flax lignan, lignan are similar to puerarin in nature and principle of action, therefore, the foregoing can also be inferred
- the estrogen-like substances and phytoestrogens of the composition will not significantly weaken the inhibitory effect of the composition on Candida albicans.
- amino acid substances such as glutamine, L-aspartic acid, asparagine, leucine, isoleucine, phenylalanine, valine, proline, Threonine is similar to glutamic acid in nature and principle of action. Therefore, it can also be inferred that the aforementioned amino acid substances will not affect the inhibitory effect of the composition on Candida albicans.
- the composition contains: 1.50% (w/w) adipic acid, 0.14% (w/w) sodium benzoate, 0.32% (w/w) phenethyl alcohol, 0.54% (w/w) propionic acid, 0.20% ( w/w) caproic acid, 0.20% (w/w) palatinose, 0.60% (w/w) maltose, 0.0005% (w/w) rose essential oil, 2.15% (w/w) xanthan gum
- Group B gel contains 2.50% (w/w) maltose, 0.20% (w/w) isomaltulose, 0.16% (w/w) sodium benzoate, 0.60% (w/w) sodium propionate, 0.35 %(W/w) phenethyl alcohol, 1.00%(w/w) citric acid, 1.168%(w/w) adipic acid, 2.15%(w/w) xanthan gum, adjust the pH to 3.6
- Group C gel contains 2.50% (w/w) maltose, 0.20% (w/w) isomaltulose, 0.16% (w/w) sodium benzoate, 0.60% (w/w) sodium propionate, 0.35 %(W/w) phenethyl alcohol, 0.61%(w/w) succinic acid, 1.168%(w/w) adipic acid, 2.15%(w/w) xanthan gum, adjust the pH to 3.6
- the second group gel contains 1.15% (w/w) sodium propionate, 0.45% (w/w) phenethyl alcohol, 0.20% (w/w) sodium benzoate, 1.50% (w/w) maltose, 1.00% (w/w) citric acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.6
- Nugent score is vaginal secretion smear and Gram staining followed by microscopic examination. The score is based on the staining, morphology, and number of bacteria, as follows:
- the vaginal bacteria are mainly gram-negative bacilli, and/or negative cocci and positive cocci, with no or very few gross positive bacilli;
- vaginal bacteria are mainly gram-negative bacilli, and/or negative cocci, and/or positive cocci, and there are few large gram-positive bacilli;
- vaginal flora is normal, and the bacteria are mainly gram-positive bacilli.
- the three groups of gels with a pH value of 3.6 in this experiment have the effects of inhibiting abnormal vaginal flora, restoring vaginal acidity, and restoring vaginal lactobacilli, containing adipic acid and 2 containing citric acid and succinic acid respectively.
- group gels (B and C groups) the effect of group B is better than that of group C and the second group of gel without adipic acid.
- the second group of gel without adipic acid inhibits abnormal vaginal flora and restores vaginal acidity
- the effect of restoring vaginal lactobacillus is the weakest among the three groups of gels.
- Group A gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.60% (w/w) butyric acid, 1.31% (w/w) adipic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 4.1
- Group B gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.60% (w/w) butyric acid, 0.0010% (w/w) capric acid, 1.31 %(W/w) adipic acid, 0.30%(w/w) phenethyl alcohol, 0.35%(w/w) malic acid, 2.15%(w/w) xanthan gum, adjust the pH to 4.1
- Group C gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.60% (w/w) butyric acid, 0.0015% (w/w) capric acid, 1.31 %(W/w) adipic acid, 0.30%(w/w) phenethyl alcohol, 0.35%(w/w) malic acid, 2.15%(w/w) xanthan gum, adjust the pH to 4.1
- the three groups of gels containing 0.60% (w/w) butyric acid, 0.00125% (w/w) decanoic acid, and 0.0015% (w/w) decanoic acid in the components of this experiment have Inhibit abnormal vaginal flora, regulate vaginal flora, restore vaginal lactobacillus, and restore normal vaginal acidity.
- the first group gel contains 0.14% (w/w) sodium benzoate, 0.54% (w/w) propionic acid, 1.46% (w/w) adipic acid, 0.30% (w/w) phenethyl alcohol, 0.35 %(W/w) malic acid, 2.15%(w/w) xanthan gum, adjust the pH to 3.8
- the second group gel contains 2.00% (w/w) maltose, 0.14% (w/w) sodium benzoate, 0.54% (w/w) propionic acid, 1.46% (w/w) adipic acid, 0.30% (w/w) Phenyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.8
- the third group of gel contains 2.0% (w/w) isomaltulose, 0.14% (w/w) sodium benzoate, 0.54% (w/w) propionic acid, 1.46% (w/w) adipic acid , 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.8
- the fourth group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) adipic acid , 0.0015% (w/w) capric acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
- the fifth group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) adipic acid , 0.01% (w/w) caprylic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
- the pH of vaginal secretions dropped to 4.1 or below in all three groups; the Nugent score of vaginal flora, two of the four cynomolgus monkeys in group 1 without sugar dropped to 4-6 points, and two dropped to 4-6 points.
- the Nugent score of vaginal flora two of the four cynomolgus monkeys in group 1 without sugar dropped to 4-6 points, and two dropped to 4-6 points.
- the pH value of this experiment is 3.8, containing 1.46% (w/w) adipic acid, 0.35% (w/w) malic acid, 0.54% (w/w) propionic acid, 0.30% (w/w) phenylethyl alcohol , 0.14% (w/w) sodium benzoate" combination, but no sugar gel, has the effect of inhibiting abnormal vaginal flora, restoring vaginal acidity, and restoring vaginal lactobacillus, as shown in the first group of experimental results.
- the gels of the second and third groups containing maltose or isomaltulose have a faster and stronger effect of restoring the vaginal lactobacillus than the gel of the first group without sugar, as shown in the second
- the results of the group experiment and the third group experiment are shown.
- the pH value of this experiment is 3.9, containing "1.31% (w/w) adipic acid, 0.35% (w/w) malic acid, 0.38% (w/w) propionic acid, 0.30% (w/w) phenylethanol” , 0.12% (w/w) sodium benzoate, 2.0% (w/w) isomaltulose, and gels containing 0.0015% (w/w) capric acid and 0.01% (w/w) caprylic acid respectively, with The effect of inhibiting abnormal vaginal flora, restoring the acidity of the vagina, and restoring the effect of vaginal lactobacillus, as shown in the results of the fourth group of experiments and the fifth group of experiments.
- the first group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) adipic acid , 0.04% (w/w) heptanoic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
- the second group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) hexamethylene Acid, 0.10% (w/w) hexanoic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
- the third group of gel contains 2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) hexamethylene Acid, 0.20% (w/w) valeric acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid, 2.15% (w/w) xanthan gum, adjust the pH to 3.9
- the pH value of this experiment is 3.9, containing "2.00% (w/w) isomaltulose, 0.12% (w/w) sodium benzoate, 0.38% (w/w) propionic acid, 1.31% (w/w) /w) adipic acid, 0.30% (w/w) phenethyl alcohol, 0.35% (w/w) malic acid” and 0.04% (w/w) heptanoic acid, 0.10% (w/w) caproic acid,
- the three groups of gels of 0.20% (w/w) valeric acid and 2.15% (w/w) xanthan gum have the effects of inhibiting abnormal vaginal flora and restoring vaginal lactobacilli.
- the two groups of gels containing 0.04% (w/w) heptanoic acid and 0.10% (w/w) caproic acid respectively have the effect of restoring the acidity of the vagina.
- the first group of gel contains 0.10% (w/w) caproic acid, 1.50% (w/w) adipic acid, 2.00% (w/w) maltose, 2.15% (w/w) xanthan gum, adjust pH to 3.1
- the second group gel contains 2.00% (w/w) propionic acid, 0.30% (w/w) cinnamyl alcohol, 0.60% (w/w) succinic acid, 2.00% (w/w) maltose, 2.15% ( w/w) Xanthan gum, adjust pH to 3.8
- the third group of gel contains 0.02% (w/w) caprylic acid, 0.25% (w/w) benzoic acid, 1.00% (w/w) citric acid, 2.00% (w/w) maltose, 2.15% (w /w) Xanthan gum, adjust the pH to 3.8
- the fourth group of gel contains 0.20% (w/w) benzoic acid, 0.25% (w/w) benzyl alcohol, 0.001% (w/w) undecanoic acid, 1.00% (w/w) malic acid, 2.00 %(W/w) maltose, 2.15%(w/w) xanthan gum, adjust the pH to 3.80
- the fifth group gel contains 0.20% (w/w) benzoic acid, 0.50% (w/w) propionic acid, 1.50% (w/w) adipic acid, 2.00% (w/w) maltose, 2.15% (w/w) Xanthan gum, adjust pH to 3.8
- the sixth group of gel contains 1.00% (w/w) pimelic acid, 0.60% (w/w) phenethyl alcohol, 1.25% (w/w) butyric acid, 2.00% (w/w) maltose, 2.15% (w/w) Xanthan gum, adjust pH to 3.8
- pH value 3.8 containing "0.20% (w/w) benzoic acid, 0.25% (w/w) benzyl alcohol, 0.001% (w/w) undecanoic acid, 1.00 %(W/w) malic acid, 2.00%(w/w) maltose, 2.15%(w/w) xanthan gum” was administered 5 times, and the pH value of vaginal secretions in 2 cynomolgus monkeys dropped to 4.6. 1 was reduced to 3.8; 1 was reduced to 4-6 points, and 1 was reduced to 0-3 points;
- pH value 3.8 containing "0.20% (w/w) benzoic acid, 0.50% (w/w) propionic acid, 1.50% (w/w) adipic acid, 2.00 %(W/w) maltose, 2.15%(w/w) xanthan gum”, after 5 times of medication, the pH value of vaginal secretions in 2 cynomolgus monkeys dropped to 4.6 and 1 dropped to 3.8; vaginal flora Nugent score 1 fell to 4-6 points, 1 fell to 0-3 points;
- pH value 3.8 containing "1.00% (w/w) pimelic acid, 0.60% (w/w) phenethyl alcohol, 1.25% (w/w) butyric acid, 2.00 %(W/w) maltose, 2.15%(w/w) xanthan gum”, after 5 times of medication, the pH value of vaginal secretions in 2 cynomolgus monkeys dropped to 3.8 and 1 dropped to 4.1; vaginal flora Nugent score 1 dropped to 0-3 points, and 1 dropped to 4-6 points.
- composition gels have the effects of inhibiting abnormal vaginal flora, restoring vaginal acidity, and restoring vaginal lactobacilli.
- the first group of gel contains 1.50% (w/w) fumaric acid, 1.00% (w/w) propionic acid, 0.08% (w/w) cinnamic acid, 0.25% (w/w) phenethyl alcohol, 1.40% ( w/w) maltose, 2.15% (w/w) xanthan gum, adjust the pH to 3.8
- the second group of gel contains 1.50% (w/w) adipic acid, 1.00% (w/w) propionic acid, 0.08% (w/w) cinnamic acid, 0.25% (w/w) phenethyl alcohol, 1.40 %(W/w) maltose, 2.15%(w/w) xanthan gum, adjust the pH to 3.8
- the gel containing 1.50% (w/w) adipic acid in this experiment has the effects of inhibiting abnormal vaginal flora, restoring vaginal lactobacilli, and restoring vaginal acidity.
- Gel A contains 1.46% (w/w) adipic acid, 0.70% (w/w) sodium propionate, 0.14% (w/w) sodium benzoate, 0.32% (w/w) phenethyl alcohol, 1.00 %(W/w) citric acid, 1.60%(w/w) maltose, 0.20%(w/w) palatinose, 0.0005%(w/w) rose essential oil, 2.15%(w/w) xanthan gum , Adjust the pH to 3.70
- the pH value is measured using a pH standard range colorimetric card.
- the colorimetric card is divided into two ranges, 3.8-4.1 indicates normal, and 4.6-5.4 indicates abnormal
- the drug was discontinued for 3 days for observation after 5 times of medication, and it had no effect on the pH value and flora of the vaginal secretions of healthy volunteers.
- the pH value of this experiment is 3.70, containing "1.46% (w/w) adipic acid, 0.70% (w/w) sodium propionate, 0.14% (w/w) sodium benzoate, 0.32% (w/w) /w) Phenyl alcohol, 1.00% (w/w) citric acid, 1.60% (w/w) maltose, 0.20% (w/w) palatinose, 0.0005% (w/w) rose essential oil, 2.15% ( w/w) “Xanthan gum” gel can significantly reduce the abnormal flora in the vagina of BV patients, significantly increase the lactobacillus, and decrease the pH value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
| 编号 | 丙酸(%) | 己二酸(%) | 苯甲醇(%) | 苯甲酸钠(%) | 抑菌率(%) |
| 1 | 0.50 | 1.50 | -- | 0.20 | 61.29 |
| 2 | 0.50 | 1.50 | 0.50 | 0.20 | 81.52 |
| 3 | 0.50 | 1.50 | 0.70 | 0.20 | 99.27 |
| 编号 | 丙酸(%) | 己二酸(%) | 苯乙醇(%) | 苯甲酸(%) | 抑菌率(%) |
| 1 | 1.50 | -- | 0.35 | 0.20 | 15.91 |
| 2 | 1.50 | -- | 0.35 | 0.25 | 46.09 |
| 3 | 1.50 | 1.50 | 0.35 | 0.20 | 67.39 |
| 4 | 1.50 | 1.50 | 0.35 | 0.25 | 92.17 |
| 编号 | 丙酸(%) | 己二酸(%) | 苯甲醇(%) | 苯甲酸钠(%) | 抑菌率(%) |
| 1 | -- | 1.35 | 0.25 | 0.20 | 45.12 |
| 2 | 0.50 | 1.35 | 0.25 | 0.20 | 61.60 |
| 3 | 1.25 | 1.35 | 0.25 | 0.20 | 89.72 |
| 4 | 1.50 | 1.35 | 0.25 | 0.20 | 94.42 |
| 5 | 3.00 | 1.35 | 0.25 | 0.20 | 100.00 |
| 编号 | 丙酸(%) | 己二酸(%) | 苯乙醇(%) | 苯甲酸(%) | 抑菌率(%) |
| 1 | 0.54 | 1.50 | 0.30 | -- | 26.05 |
| 2 | 0.54 | 1.50 | 0.30 | 0.50 | 64.80 |
| 3 | 0.54 | 1.50 | 0.30 | 1.00 | 100.00 |
| 编号 | 丙酸(%) | 己二酸(%) | 苯乙醇(%) | 苯甲酸钠(%) | 抑菌率(%) |
| 1 | -- | 1.50 | 0.30 | 1.18 | 84.12 |
| 2 | 2.00 | 1.50 | 0.30 | 1.18 | 100.00 |
| 编号 | 丁酸(%) | 己酸(%) | 己二酸(%) | 苯乙醇(%) | 苯氧乙醇(%) | 苯甲酸钠(%) | 抑菌率(%) |
| 1 | 0.88 | -- | -- | 0.40 | -- | 0.20 | 71.52 |
| 2 | -- | 0.12 | -- | 0.40 | -- | 0.20 | 70.65 |
| 3 | 0.88 | -- | -- | -- | 0.40 | 0.20 | 56.75 |
| 4 | -- | 0.12 | -- | -- | 0.40 | 0.20 | 35.88 |
| 5 | 0.88 | -- | 1.46 | 0.40 | -- | 0.20 | 100.00 |
| 6 | -- | 0.12 | 1.46 | 0.40 | -- | 0.20 | 100.00 |
| 7 | 0.88 | -- | 1.46 | -- | 0.40 | 0.20 | 100.00 |
| 8 | -- | 0.12 | 1.46 | -- | 0.40 | 0.20 | 100.00 |
| 编号 | 丙酸(%) | 庚二酸(%) | 苹果酸(%) | 苯乙醇(%) | 对羟基苯甲酸(%) | 抑菌率(%) |
| 1 | 2.50 | -- | -- | 0.06 | 0.21 | 62.76 |
| 2 | 2.50 | 1.60 | -- | 0.06 | 0.21 | 94.84 |
| 3 | 2.50 | -- | 1.34 | 0.06 | 0.21 | 65.68 |
| 编号 | 己二酸(%) | 丁酸(%) | 苯甲酸钠(%) | 苯乙醇(%) | 抑菌率(%) |
| 1 | 1.46 | -- | -- | -- | 11.52 |
| 2 | -- | 0.60 | -- | -- | 1.57 |
| 3 | -- | -- | 0.14 | -- | 19.90 |
| 4 | -- | -- | -- | 0.40 | -1.05 |
| 5 | 1.46 | 0.60 | -- | -- | 13.61 |
| 6 | -- | 0.60 | 0.14 | -- | 17.80 |
| 7 | -- | 0.60 | -- | 0.40 | 8.90 |
| 8 | 1.46 | 0.60 | 0.14 | -- | 27.23 |
| 9 | 1.46 | 0.60 | -- | 0.40 | 25.65 |
| 10 | -- | 0.60 | 0.14 | 0.40 | 2.62 |
| 11 | 1.46 | -- | 0.14 | 0.40 | 42.41 |
| 12 | 1.46 | 0.60 | 0.14 | 0.40 | 89.53 |
| 编号 | 己酸(%) | 己二酸(%) | 苯甲酸钠(%) | 苯乙醇(%) | 抑菌率(%) |
| 1 | 0.18 | -- | -- | -- | 2.82 |
| 2 | -- | 1.35 | -- | -- | 5.81 |
| 3 | -- | -- | 0.20 | -- | 6.95 |
| 4 | -- | -- | -- | 0.30 | 0.59 |
| 5 | 0.18 | 1.35 | 0.20 | 0.30 | 58.86 |
| 6 | 0.18 | 1.35 | 0.20 | -- | 25.17 |
| 7 | 0.18 | 1.35 | -- | 0.30 | 9.33 |
| 8 | -- | 1.35 | 0.20 | 0.30 | 15.37 |
| 9 | 0.18 | -- | 0.20 | 0.30 | 28.78 |
| 编号 | 丙酸(%) | 己二酸(%) | 肉桂酸(%) | 苯乙醇(%) | 水杨酸(%) | 抑菌率(%) |
| 1 | 1.50 | 1.50 | -- | 0.45 | -- | 30.96 |
| 2 | 1.50 | 1.50 | 0.03 | 0.45 | -- | 59.04 |
| 3 | 1.50 | 1.50 | 0.05 | 0.45 | -- | 71.19 |
| 4 | 1.50 | 1.50 | 0.08 | 0.45 | -- | 96.38 |
| 5 | 1.50 | 1.50 | 0.10 | 0.45 | -- | 100.00 |
| 6 | 1.50 | 1.50 | -- | 0.45 | 0.03 | 37.40 |
| 7 | 1.50 | 1.50 | -- | 0.45 | 0.05 | 55.58 |
| 8 | 1.50 | 1.50 | -- | 0.45 | 0.08 | 86.96 |
| 9 | 1.50 | 1.50 | -- | 0.45 | 0.10 | 94.81 |
| 编号 | 丁酸(%) | 庚二酸(%) | 苯乙醇(%) | 抑菌率(%) |
| 1 | 1.00 | -- | -- | 1.22 |
| 2 | -- | 1.00 | -- | 2.09 |
| 3 | -- | -- | 0.60 | 4.98 |
| 4 | 1.00 | -- | 0.60 | 11.09 |
| 5 | 1.00 | 1.00 | 0.60 | 65.22 |
| 编号 | 丙酸(%) | 庚二酸(%) | 肉桂醇(%) | 苯甲酸钠(%) | 抑菌率(%) |
| 1 | 2.00 | 1.50 | -- | 0.20 | 41.25 |
| 2 | 2.00 | 1.50 | 0.03 | 0.20 | 72.15 |
| 3 | 2.00 | 1.50 | 0.05 | 0.20 | 84.54 |
| 4 | 2.00 | 1.50 | 0.08 | 0.20 | 95.21 |
| 编号 | 丙酸(%) | 庚二酸(%) | 苯甲酸钠(%) | 抑菌率(%) |
| 1 | -- | 5.00 | -- | 15.42 |
| 2 | -- | -- | 1.18 | 15.92 |
| 3 | 0.10 | -- | -- | 2.90 |
| 4 | 0.10 | 5.00 | 1.18 | 61.02 |
Claims (24)
- 一种抑菌组合物,其特征在于,包含以下组分:(1)一种或多种脂肪酸和/或其盐,所述脂肪酸选自由乙酸、羟基乙酸、乳酸、丙酸、乙酰丙酸、丁酸、异丁酸、羟基丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,以脂肪酸计组分(1)的总含量在0.001-3.00%(w/w)范围内;(2)一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,以二元酸计组分(2)的总含量在0.05-5.00%(w/w)范围内;(3)一种或多种芳香醇,所述芳香醇选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,组分(3)的总含量在0.03-1.00%(w/w)范围内;(4)一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,以芳香酸计组分(4)的总含量在0.03-1.00%(w/w)范围内;所述抑菌组合物的剂型选自由水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂组成的组的一种。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物中组分(1)的总含量在0.001-2.00%(w/w)范围内;且/或组分(2)的总含量在0.10-3.50%(w/w)范围内;且/或组分(3)的总含量在0.03-0.70%(w/w)范围内;且/或组分(4)的总含量在0.03-0.50%(w/w)范围内。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物中进一步包含组分(5):选自由苹果酸、柠檬酸、琥珀酸、酒石酸、马来酸、以及异柠檬酸组成的组的一种或多种二元酸和/或多元酸,和/或其盐,其总 含量在0.10-2.50%(w/w)范围内。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物中进一步包含一种或多种糖,所述糖选自由葡萄糖、果糖、甘露糖、半乳糖、麦芽糖、异麦芽糖、蔗糖、异麦芽酮糖、乳糖、乳果糖、海藻糖、纤维二糖、蜜二糖、龙胆二糖、蔗果三糖、蔗果四糖、蔗果五糖、异麦芽三糖、异麦芽四糖、异麦芽五糖、低聚龙胆糖、棉子糖、潘糖、麦芽寡糖、低聚异麦芽酮糖、低聚果糖、葡甘聚糖、低聚半乳糖、糊精、淀粉、以及糖原组成的组,其总含量在0.01-20.00%(w/w)范围内,优选总含量在0.10-2.00%(w/w)范围内。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种氨基酸和/或其盐,所述氨基酸选自由L-谷氨酸、谷氨酰胺、L-天冬氨酸、天冬氨酰胺、亮氨酸、异亮氨酸、苯丙氨酸、缬氨酸、脯氨酸、以及苏氨酸组成的组,其总含量在0.10-6.00%(w/w)范围内,优选总含量在0.50-3.00%(w/w)范围内。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种单萜或倍半萜类化合物,所述单萜或倍半萜类化合物选自由香茅醇、芳樟醇、香叶醇、橙花醇、桉叶醇、松油醇、香芹醇、薄荷醇、以及薰衣草醇组成的组。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种植物芳香油类物质,所述植物芳香油类物质选自由玫瑰精油、丁香油、麝香草油、薰衣草油、薄荷油、艾叶油、桉叶油、黄樟油、山苍子精油、肉桂精油、月桂叶油、以及百里香油组成的组。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种维生素,所述维生素选自由维生素A、维生素C、维生素D、以及维生素E组成的组。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种选自下组的物质:脱氢乙酸、脱氢乙酸钠、山梨酸、山梨酸钾、山梨酸钠、纳他霉素、岩白菜素、环庚三烯酚酮、肉桂醛、土槿乙酸、绿原酸、1,2-戊二醇、1,2-己二醇、1,6-己二醇、1,2-辛二醇、1,2-癸二醇、对羟基苯乙酮、2,4-二羟基苯乙酮、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、溶菌酶、单辛酸甘油酯、单癸酸甘油酯、以及单月桂酸甘油酯。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物进一步包含一种或多种抗菌药物,所述抗菌药物选自由硝基咪唑类药物,如甲硝唑、替硝唑、奥硝唑;氨基糖甙类药物,如庆大霉素、妥布霉素、阿米卡星、西索米星、奈替米星;喹诺酮类药物,如环丙沙星、氧氟沙星、左氧氟沙星;呋喃类药物,如硝呋太尔、硝呋醛肟、呋喃西林、呋喃唑酮、呋喃妥因;磺胺类药物,如磺胺嘧啶银、磺胺醋酰钠;吡咯类药物,如克霉唑、氟康唑、咪康唑、酮康唑;丙烯胺类药物,如萘替芬、特比萘芬;多烯类抗生素,如两性霉素B、制霉菌素、制酵母菌素、以及纳他霉素组成的组。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物为pH值在3.1-4.8范围内,优选3.6-4.6范围内,更优选3.8-4.4范围内的水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、以及软膏剂。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物 为治疗性产品、或其有效组分、或其防腐剂,其中所述治疗性产品以下组中的一种形式存在:药品、消毒剂、抗菌剂、抑菌剂、皮肤黏膜表面杀微生物剂、菌群调节剂、微生态调节剂、微环境调节剂、微生物调节剂、一次性使用医疗用品,或者以医疗器械、药物器械、消毒器械、以及阴道用器械的组成部分的形式存在。
- 根据权利要求1所述的抑菌组合物,其特征在于,所述抑菌组合物为非治疗性产品、或其有效组分、或其防腐剂,其中所述非治疗性产品以下组中的其中一种形式存在:保健用品、卫生用品、个人洗护用品、化妆品、一次性使用卫生用品、清洁用品、日用品、微生态护理品、除异味剂、润滑剂、湿润剂、洗剂、清洁剂、养护剂、止痒剂、清新剂,或者以卫生巾、卫生护垫、以及卫生棉条的组成部分的形式存在。
- 根据权利要求1所述的抑菌组合物,其特征在于,其中所述抑菌组合物为阴道用抑菌组合物,所述阴道用抑菌组合物包括以下组分:(1)一种或多种脂肪酸和/或其盐,所述脂肪酸选自由乙酸、羟基乙酸、乳酸、丙酸、乙酰丙酸、丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,以脂肪酸计的组分(1)的总含量在0.001-2.00%(w/w)范围内;(2)一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,以二元酸计的组分(2)的总含量在0.50-2.50%(w/w)范围内;(3)一种或多种芳香醇,所述芳香醇选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,组分(3)其总含量在0.05-0.60%(w/w)范围内;(4)一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基 苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,以芳香酸计的组分(4)的总含量在0.05-0.25%(w/w)范围内。所述阴道用抑菌组合物的剂型选自由水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂组成的组。
- 一种抑制有害微生物的方法,其特征在于,包括使用根据权利要求1-14任一项所述的抑菌组合物的步骤。
- 根据权利要求15的方法,其特征在于,所述有害微生物包括:假丝酵母菌、金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌、阴道加德纳菌、普雷沃菌、动弯杆菌、黑曲霉菌、以及人体皮肤和/或黏膜部位的异常菌群。
- 一种调节阴道菌群的方法,其特征在于,包括使用阴道用抑菌组合物的步骤,其中,所述阴道用抑菌组合物含有一种或多种脂肪酸和/或其盐,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组,以脂肪酸计的所述脂肪酸和/或其盐的总含量在0.001-2.00%(w/w)范围内;其中,所述阴道用抑菌组合物的剂型选自由水溶液剂、水溶性凝胶剂、泡沫剂、喷雾剂、软膏剂、散剂、膜剂、胶囊剂、栓剂、以及片剂组成的组;所述调节阴道菌群包括下述中的至少一种:抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌。
- 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种二元酸和/或其盐,所述二元酸选自由戊二酸、己二酸、以及庚二酸组成的组,以二元酸计的所述二元酸和/或其盐的总含量在0.50-2.50%(w/w)范围内。
- 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种芳香醇,所述芳香醇选自由苯甲醇、2,4-二氯苯甲醇、苯乙醇、苯氧乙醇、以及肉桂醇组成的组,其总含量在0.05-0.60%(w/w)范围内。
- 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种芳香酸和/或其盐,所述芳香酸选自由苯甲酸、对羟基苯甲酸、对甲氧基苯甲酸、水杨酸、肉桂酸、龙胆酸、以及咖啡酸组成的组,以芳香酸计的所述芳香酸和/或其盐的总含量在0.05-0.25%(w/w)范围内。
- 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物进一步包含一种或多种雌激素或植物雌激素类物质,所述雌激素或植物雌激素类物质选自由己烯雌酚、己烷雌酚、雌二醇、雌酮、雌三醇、尼尔雌醇、炔雌醇、炔雌醇环戊醚、炔雌甲醚、普罗雌烯、大豆苷、黄豆苷元、黄豆黄素、葛根素、拟雌内酯、金雀异黄酮、雌马醇、芹黄素、染料木甙、染料木素、鸡豆黄素、香豆雌酚、芒柄花黄素、白藜芦醇、亚麻木酚素、以及木脂素组成的组,其总含量在0.001-1.00%(w/w)范围内。
- 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物用于包括恢复和/或维护阴道正常菌群、和/或恢复和/或维护阴道的正常微生态、和/或恢复和/或维护阴道的正常酸度、和/或清洁护理阴道和/或外阴,和/或减轻和/或消除阴道外阴瘙痒、和/或疼痛、和/或干涩、和/或刺激、和/或性交不适,和/或减轻和/或消除白带异常、和/或白带异味。
- 根据权利要求17所述的方法,其特征在于,所述阴道用抑菌组合物 用于预防和/或治疗阴道菌群失调、和/或细菌性阴道病、和/或需氧菌性阴道炎、和/或细胞溶解性阴道病、和/或阴道外阴假丝酵母菌病、和/或萎缩性阴道炎。
- 脂肪酸和/或其盐在制备用于调节阴道菌群的抑菌组合物中的用途,其特征在于,所述脂肪酸选自由丁酸、戊酸、己酸、庚酸、辛酸、壬酸、癸酸、十一酸、十一烯酸、以及月桂酸组成的组中的至少一种,以脂肪酸计的所述脂肪酸和/或其盐在抑菌组合物中的总含量在0.001-2.00%(w/w)范围内,所述调节阴道菌群包括下述中的至少一种:抑制阴道异常菌群、恢复和/或维护阴道的乳杆菌。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21753951.9A EP4101437B1 (en) | 2020-02-12 | 2021-02-05 | Bacteriostatic composition, preparation method therefor and use thereof |
| CA3167761A CA3167761C (en) | 2020-02-12 | 2021-02-05 | BACTERIOSTATIC COMPOSITION, PREPARATION PROCESS AND USE |
| CN202180014214.2A CN115515556B (zh) | 2020-02-12 | 2021-02-05 | 抑菌组合物及其制备方法和用途 |
| US17/886,476 US20220395481A1 (en) | 2020-02-12 | 2022-08-12 | Bacteriostatic composition, preparation method therefor, and use thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010101402 | 2020-02-12 | ||
| CN202010101402.6 | 2020-02-12 | ||
| CN202011324292 | 2020-11-15 | ||
| CN202011324292.6 | 2020-11-15 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/886,476 Continuation US20220395481A1 (en) | 2020-02-12 | 2022-08-12 | Bacteriostatic composition, preparation method therefor, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021160049A1 true WO2021160049A1 (zh) | 2021-08-19 |
Family
ID=77291383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/075655 Ceased WO2021160049A1 (zh) | 2020-02-12 | 2021-02-05 | 抑菌组合物及其制备方法和用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220395481A1 (zh) |
| EP (1) | EP4101437B1 (zh) |
| CA (1) | CA3167761C (zh) |
| WO (1) | WO2021160049A1 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113605090A (zh) * | 2021-09-06 | 2021-11-05 | 安徽高梵电子商务有限公司 | 一种羽绒服除味清新喷雾及其制备方法 |
| CN113718530A (zh) * | 2021-09-06 | 2021-11-30 | 安徽高梵电子商务有限公司 | 一种含有海洋生物成分的羽绒服除味剂 |
| CN113756103A (zh) * | 2021-09-06 | 2021-12-07 | 安徽高梵电子商务有限公司 | 羽绒服腥味快速去除喷雾及其制备方法 |
| CN114903918A (zh) * | 2022-05-27 | 2022-08-16 | 北京恩吉赛生物科技有限公司 | 女性微生态抑菌修复凝胶及制备方法和应用 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116019766A (zh) * | 2023-02-10 | 2023-04-28 | 陕西文锐医疗器械有限公司 | 一种氨基酸多肽抑菌凝胶及其制备方法和应用 |
| CN116077488B (zh) * | 2023-02-22 | 2024-11-15 | 西南医科大学 | 雌马酚在防治病原真菌和细菌感染中的医药新应用 |
| CN116210697B (zh) * | 2023-03-02 | 2024-05-14 | 西北农林科技大学 | 反式肉桂酸在提高苹果树腐烂病抗性中的应用 |
| CN117100904A (zh) * | 2023-09-19 | 2023-11-24 | 浙江大学 | 一种由明胶、透明质酸和月桂酸组成的糖尿病感染伤口水凝胶敷料及其制备方法 |
| CN117338636B (zh) * | 2023-12-04 | 2024-02-23 | 江西中医药大学 | 一种用于精油缓释的材料及其应用 |
| CN117717612B (zh) * | 2023-12-19 | 2024-10-01 | 中山自然说生物科技有限公司 | 一种私密护理组合物及其制备方法和应用 |
| WO2025188334A1 (en) * | 2024-03-08 | 2025-09-12 | Lanxess Corporation | Antimicrobial compositions comprising fatty acid antimicrobial boosters, stabilized compositions thereof, and applications thereof in product formulations |
| CN120204075A (zh) * | 2025-03-11 | 2025-06-27 | 谷雨生物科技集团股份有限公司 | 一种防腐抗菌组合物及其制备方法与应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002322090A (ja) * | 2001-04-27 | 2002-11-08 | Kao Corp | 抗菌性組成物 |
| WO2011041938A1 (zh) * | 2009-10-08 | 2011-04-14 | 富莱生物技术投资有限公司 | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 |
| CN103648482A (zh) * | 2011-07-15 | 2014-03-19 | 根特大学 | 阴道内递送系统 |
| WO2015135470A1 (zh) * | 2014-03-13 | 2015-09-17 | 曾忠铭 | 一种阴道用组合物与该组合物的用途 |
| WO2019147875A1 (en) * | 2018-01-26 | 2019-08-01 | The Procter & Gamble Company | Methods and compositions for reducing the feeling of vaginal dryness |
| CN110368324A (zh) * | 2019-08-28 | 2019-10-25 | 海南厢珠物联科技股份有限公司 | 一种抑制大肠杆菌,白色念珠菌,金黄色葡萄球菌的制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670160A (en) * | 1990-08-24 | 1997-09-23 | Schulke & Mayr Gmbh | Preservatives and their use |
| US20070292355A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
| US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
| ITMI20131971A1 (it) * | 2013-11-26 | 2015-05-27 | Fidia Farmaceutici | Composizioni farmaceutiche ad attività idratante e lubrificante |
| EP3520785B1 (en) * | 2016-10-09 | 2024-07-17 | Shenzhen Eulikan Biotechnology Co., Ltd. | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use |
-
2021
- 2021-02-05 WO PCT/CN2021/075655 patent/WO2021160049A1/zh not_active Ceased
- 2021-02-05 CA CA3167761A patent/CA3167761C/en active Active
- 2021-02-05 EP EP21753951.9A patent/EP4101437B1/en active Active
-
2022
- 2022-08-12 US US17/886,476 patent/US20220395481A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002322090A (ja) * | 2001-04-27 | 2002-11-08 | Kao Corp | 抗菌性組成物 |
| WO2011041938A1 (zh) * | 2009-10-08 | 2011-04-14 | 富莱生物技术投资有限公司 | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 |
| US8765819B2 (en) | 2009-10-08 | 2014-07-01 | Zhongming Zeng | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof |
| CN103648482A (zh) * | 2011-07-15 | 2014-03-19 | 根特大学 | 阴道内递送系统 |
| WO2015135470A1 (zh) * | 2014-03-13 | 2015-09-17 | 曾忠铭 | 一种阴道用组合物与该组合物的用途 |
| WO2019147875A1 (en) * | 2018-01-26 | 2019-08-01 | The Procter & Gamble Company | Methods and compositions for reducing the feeling of vaginal dryness |
| CN110368324A (zh) * | 2019-08-28 | 2019-10-25 | 海南厢珠物联科技股份有限公司 | 一种抑制大肠杆菌,白色念珠菌,金黄色葡萄球菌的制剂 |
Non-Patent Citations (4)
| Title |
|---|
| "Pharmacopoeia of the People's Republic of China", vol. IV, 2020, article "Bacteriostatic Effectiveness Testing" |
| BORGES SANDRA, SILVA JOANA, TEIXEIRA PAULA: "The role of lactobacilli and probiotics in maintaining vaginal health", ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol. 289, no. 3, 1 March 2014 (2014-03-01), DE, pages 479 - 489, XP055835465, ISSN: 0932-0067, DOI: 10.1007/s00404-013-3064-9 * |
| FANG LIANG: "Pharmaceutics", 2016, PEOPLE'S MEDICAL PUBLISHING HOUSE, pages: 280 - 284 |
| See also references of EP4101437A4 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113605090A (zh) * | 2021-09-06 | 2021-11-05 | 安徽高梵电子商务有限公司 | 一种羽绒服除味清新喷雾及其制备方法 |
| CN113718530A (zh) * | 2021-09-06 | 2021-11-30 | 安徽高梵电子商务有限公司 | 一种含有海洋生物成分的羽绒服除味剂 |
| CN113756103A (zh) * | 2021-09-06 | 2021-12-07 | 安徽高梵电子商务有限公司 | 羽绒服腥味快速去除喷雾及其制备方法 |
| CN113718530B (zh) * | 2021-09-06 | 2023-01-31 | 安徽高梵电子商务有限公司 | 一种含有海洋生物成分的羽绒服除味剂 |
| CN113756103B (zh) * | 2021-09-06 | 2023-01-31 | 安徽高梵电子商务有限公司 | 羽绒服腥味快速去除喷雾及其制备方法 |
| CN113605090B (zh) * | 2021-09-06 | 2023-01-31 | 安徽高梵电子商务有限公司 | 一种羽绒服除味清新喷雾及其制备方法 |
| CN114903918A (zh) * | 2022-05-27 | 2022-08-16 | 北京恩吉赛生物科技有限公司 | 女性微生态抑菌修复凝胶及制备方法和应用 |
| CN114903918B (zh) * | 2022-05-27 | 2024-04-16 | 北京恩吉赛生物科技有限公司 | 女性微生态抑菌修复凝胶及制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4101437B1 (en) | 2025-06-11 |
| CA3167761A1 (en) | 2021-08-19 |
| US20220395481A1 (en) | 2022-12-15 |
| CA3167761C (en) | 2025-05-20 |
| EP4101437A1 (en) | 2022-12-14 |
| EP4101437A4 (en) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021160049A1 (zh) | 抑菌组合物及其制备方法和用途 | |
| EP3520785B1 (en) | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use | |
| EP1072269B1 (en) | Use of dextrin, starch or glycogen for the treatment of bacterial vaginosis | |
| US11951116B2 (en) | Vaginal composition and use thereof | |
| EP1911454B1 (en) | A composition and method of regulating and maintaining the vaginal bacterial flora and the normal acidity in the vagina | |
| CN102470117B (zh) | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 | |
| CN115515556B (zh) | 抑菌组合物及其制备方法和用途 | |
| KR20110139298A (ko) | 아토포비움 종에 의해 야기된 감염을 치료하기 위한 니푸라텔의 용도 | |
| EP2643003B1 (en) | Vaginal composition based on alkyl polyglucosides | |
| EP1646378B1 (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences | |
| US6964949B2 (en) | Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof | |
| CN112773780A (zh) | 一种阴道外阴用组合物及其用途 | |
| KR102784739B1 (ko) | 질 세정용 조성물 | |
| HK1092693B (zh) | 用於治疗真菌双重感染和真菌复发的包含抗坏血酸的药物组合物 | |
| CN102985138A (zh) | 用于治疗妇科疾病的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21753951 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: 3167761 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021753951 Country of ref document: EP Effective date: 20220912 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2021753951 Country of ref document: EP |













































